| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Karina Zanlorenzi Basso Manosso, Carolina Labigalini Sampaio, Leandro Kasuki, Ximene Antunes, Monica R Gadelha, Cesar Luiz Boguszewsk. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. Endocrine. vol 74. issue 1. 2021-10-25. PMID:34041695. |
gh and igf-i levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in brazil. |
2021-10-25 |
2023-08-13 |
Not clear |
| Karina Zanlorenzi Basso Manosso, Carolina Labigalini Sampaio, Leandro Kasuki, Ximene Antunes, Monica R Gadelha, Cesar Luiz Boguszewsk. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. Endocrine. vol 74. issue 1. 2021-10-25. PMID:34041695. |
to compare biochemical and tumor response rates between two reference centers for pituitary diseases in brazil after primary and adjuvant therapy with somatostatin receptor ligands (srl) in acromegaly. |
2021-10-25 |
2023-08-13 |
Not clear |
| Lena Rass, Amir-Hossein Rahvar, Jakob Matschke, Wolfgang Saeger, Thomas Renné, Jens Aberle, Jörg Flitsch, Roman Rotermun. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones (Athens, Greece). 2021-10-21. PMID:34674191. |
differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? |
2021-10-21 |
2023-08-13 |
Not clear |
| Ayse S Akdemir, Derya Metin Armagan, Ozge Polat Korkmaz, Hande M Ozkaya, Pinar Kadioglu, Nurperi Gazioglu, Necmettin Tanriover, Ahmet Dirican, Melek Oztur. Association between β arrestin 2 and filamin A gene variations with medical treatment response in acromegaly patients. Minerva endocrinology. 2021-10-20. PMID:34669321. |
some acromegaly patients show resistance to somatostatin analog (ssa) treatment. |
2021-10-20 |
2023-08-13 |
Not clear |
| Ming Shen, Yeping Yang, Wenqiang He, Nidan Qiao, Min He, Xuefei Shou, Meng Wang, Zengyi Ma, Zhao Ye, Yichao Zhang, Zhengyuan Chen, Qilin Zhang, Xiang Zhou, Xiaoyun Cao, Hongying Ye, Yongfei Wang, Shiqi Li, Yiming Li, Yao Zhao, Zhaoyun Zhan. Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 55. 2021-10-12. PMID:33011455. |
efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: a hospital-based study of 237 cases. |
2021-10-12 |
2023-08-13 |
Not clear |
| Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuk. The future of somatostatin receptor ligands in acromegaly. The Journal of clinical endocrinology and metabolism. 2021-10-07. PMID:34618894. |
the future of somatostatin receptor ligands in acromegaly. |
2021-10-07 |
2023-08-13 |
Not clear |
| Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuk. The future of somatostatin receptor ligands in acromegaly. The Journal of clinical endocrinology and metabolism. 2021-10-07. PMID:34618894. |
currently, first-generation somatostatin receptor ligands (fg-srls), octreotide lar and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. |
2021-10-07 |
2023-08-13 |
Not clear |
| Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Renan Lyra Miranda, Paula C L Elias, Nina R de Castro Musolino, Debora Nazato, Raquel Jallad, Martha K P Huayllas, Jose Italo S Mota, Tobias Almeida, Evandro Portes, Antonio Ribeiro-Oliveira, Lucio Vilar, Cesar Luiz Boguszewski, Ana Beatriz Winter Tavares, Vania S Nunes-Nogueira, Tânia Longo Mazzuco, Carolina Garcia Soares Leães Rech, Nelma Veronica Marques, Leila Chimelli, Mauro Czepielewski, Marcello D Bronstein, Julio Abucham, Margaret de Castro, Leandro Kasuki, Mônica Gadelh. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. The Journal of clinical endocrinology and metabolism. vol 106. issue 7. 2021-10-04. PMID:33686418. |
machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. |
2021-10-04 |
2023-08-13 |
Not clear |
| Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Renan Lyra Miranda, Paula C L Elias, Nina R de Castro Musolino, Debora Nazato, Raquel Jallad, Martha K P Huayllas, Jose Italo S Mota, Tobias Almeida, Evandro Portes, Antonio Ribeiro-Oliveira, Lucio Vilar, Cesar Luiz Boguszewski, Ana Beatriz Winter Tavares, Vania S Nunes-Nogueira, Tânia Longo Mazzuco, Carolina Garcia Soares Leães Rech, Nelma Veronica Marques, Leila Chimelli, Mauro Czepielewski, Marcello D Bronstein, Julio Abucham, Margaret de Castro, Leandro Kasuki, Mônica Gadelh. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. The Journal of clinical endocrinology and metabolism. vol 106. issue 7. 2021-10-04. PMID:33686418. |
artificial intelligence (ai), in particular machine learning (ml), may be used to deeply analyze biomarkers of response to first-generation somatostatin receptor ligands (fg-srls) in the treatment of acromegaly. |
2021-10-04 |
2023-08-13 |
Not clear |
| Nina Ionovici, Mara Carsote, Dana Cristina Terzea, Anca Mihaela Predescu, Anne Marie Rauten, Mihaela Popesc. Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. vol 61. issue 2. 2021-09-16. PMID:33544787. |
this is a narrative review of literature introducing somatostatin receptors (sstrs) as part of understanding the somatotroph cells since they are positive in normal cells but also in tumoral cells as seen in somatotropinoma, a growth hormone (gh)-producing neoplasia, which causes acromegaly. |
2021-09-16 |
2023-08-13 |
human |
| Maria Stelmachowska-Banaś, Izabella Czajka-Oraniec, Agnieszka Tomasik, Wojciech Zgliczyńsk. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary. 2021-09-09. PMID:34498217. |
pasireotide-lar, a second-generation somatostatin receptor ligand (srl), is recommended for patients with acromegaly as second-line treatment. |
2021-09-09 |
2023-08-13 |
Not clear |
| Serdar Sahin, Mehmet Cem Fidan, Ozge Polat Korkmaz, Emre Durcan, Hande Mefkure Ozkaya, Pinar Kadiogl. Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 129. issue 9. 2021-09-06. PMID:33096579. |
to evaluate the effectiveness of cabergoline and the parameters affecting cabergoline response as add-on treatment to somatostatin analaogues (ssa) in patients with acromegaly uncontrolled with ssas. |
2021-09-06 |
2023-08-13 |
Not clear |
| Joan Gil, Mireia Jordà, Berta Soldevila, Manel Puig-Doming. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly. Frontiers in endocrinology. vol 12. 2021-08-27. PMID:33790868. |
epithelial-mesenchymal transition in the resistance to somatostatin receptor ligands in acromegaly. |
2021-08-27 |
2023-08-13 |
Not clear |
| Joan Gil, Mireia Jordà, Berta Soldevila, Manel Puig-Doming. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly. Frontiers in endocrinology. vol 12. 2021-08-27. PMID:33790868. |
different studies have shown the association of emt with increased tumor size and invasion in pituitary tumors, and in particular with a poor response to somatostatin receptor ligands (srls) treatment in gh-producing pituitary tumors, the main cause of acromegaly. |
2021-08-27 |
2023-08-13 |
Not clear |
| Manel Puig-Domingo, Joan Gil, Miguel Sampedro-Nuñez, Mireia Jordà, Susan M Webb, Guillermo Serra, Laura Pons, Isabel Salinas, Alberto Blanco, Montserrat Marques-Pamies, Elena Valassi, Antonio Picó, Araceli García-Martínez, Cristina Carrato, Raquel Buj, Carlos Del Pozo, Gabriel Obiols, Carles Villabona, Rosa Cámara, Carmen Fajardo-Montañana, Clara V Alvarez, Ignacio Bernabéu, Mónica Marazuel. Molecular profiling for acromegaly treatment: a validation study. Endocrine-related cancer. vol 27. issue 6. 2021-08-23. PMID:32302973. |
pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the first-generation somatostatin receptor ligands (srl) being the first-line treatment. |
2021-08-23 |
2023-08-13 |
Not clear |
| Laura E Dichtel, Allison Kimball, Kevin C J Yuen, Whitney Woodmansee, Melanie S Haines, Qiu Xia Guan, Brooke Swearingen, Lisa B Nachtigall, Nicholas A Tritos, Julie L Sharpless, Ursula B Kaiser, Anu V Gerweck, Karen K Mille. Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clinical endocrinology. vol 94. issue 1. 2021-08-18. PMID:32779234. |
effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. |
2021-08-18 |
2023-08-13 |
Not clear |
| Laura E Dichtel, Allison Kimball, Kevin C J Yuen, Whitney Woodmansee, Melanie S Haines, Qiu Xia Guan, Brooke Swearingen, Lisa B Nachtigall, Nicholas A Tritos, Julie L Sharpless, Ursula B Kaiser, Anu V Gerweck, Karen K Mille. Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clinical endocrinology. vol 94. issue 1. 2021-08-18. PMID:32779234. |
we investigated the effects of biochemical control of acromegaly by growth hormone receptor antagonism vs somatostatin analog therapy on qol. |
2021-08-18 |
2023-08-13 |
Not clear |
| Giovanni Tulipano, Andrea Giustin. Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. Reviews in endocrine & metabolic disorders. vol 22. issue 2. 2021-08-16. PMID:33821422. |
autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. |
2021-08-16 |
2023-08-13 |
Not clear |
| Giovanni Tulipano, Andrea Giustin. Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. Reviews in endocrine & metabolic disorders. vol 22. issue 2. 2021-08-16. PMID:33821422. |
nevertheless, some recent articles joint to previous case studies, suggest that this process plays a role in the modulation and fluctuation of normal pituitary cell functions and in the response of pituitary tumor cells to drug therapy, including the response to somatostatin receptor ligand (srls), the first-line medical therapy of acromegaly. |
2021-08-16 |
2023-08-13 |
Not clear |
| Przemysław Witek, Marek Bolanowski, Katarzyna Szamotulska, Agnieszka Wojciechowska-Luźniak, Aleksandra Jawiarczyk-Przybyłowska, Marcin Kałużn. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. Frontiers in endocrinology. vol 12. 2021-08-10. PMID:33776927. |
the aim of the study was to evaluate glucose metabolism, as measured by glycated hemoglobin (hba1c) levels and the need for antidiabetic medical treatment, in patients with acromegaly resistant to first-generation somatostatin receptors ligands (srls) treated with pasireotide long-acting release (lar) in real-world clinical practice. |
2021-08-10 |
2023-08-13 |
Not clear |